leadership team
Meet the Lipid Management Team
Our team of industry leaders at ESPERION has proven expertise in understanding cholesterol biosynthesis. Our team combines excellence in drug development with superior business skills, demonstrating a commitment to providing patients and physicians new oral therapies to reduce LDL-C.

The Lipid Management Team at ESPERION has deep and broad relationships with other industry-leading experts and businesses, enabling them to extend their impact where and when needed.

Tim Mayleben is President and Chief Executive Officer and has been a member of our board of directors since February 2010.

Prior to joining ESPERION, Tim was President, Chief Executive Officer, and a director of Vericel Corporation, formerly Aastrom Biosciences, Inc.

Previously, Tim was President, Chief Operating Officer, and a director of NightHawk Radiology Holdings, Inc. Prior to joining NightHawk, Tim was the Chief Operating Officer of the original ESPERION, until its acquisition by Pfizer in 2004.

Tim is an advisor to, investor in, and member of the board of directors of Marinus Pharmaceuticals. He has previously been involved with several life science companies, including Kaléo Pharma, LOXO Oncology, and the Wolverine Venture Fund.

Tim earned an MBA, with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University, and a BBA from the University of Michigan, Ross School of Business.

Rick Bartram is Chief Financial Officer. Prior to joining ESPERION, Rick was Assurance Manager with PricewaterhouseCoopers (PwC) where he held various positions of increasing responsibility over almost eight years with the firm.

Rick earned an MS in Accounting from Michigan State University and a BA, with honor, in accounting from Michigan State University. Rick is also a Certified Public Accountant.

Sheldon is an accomplished leader in the cardiovascular space and brings over 25 years of leadership roles to Esperion. Most recently, he was with chief commercial officer at Portola pharmaceuticals until it was acquired by Alexion. Prior to joining Portola, Sheldon was senior vice president and head of the cardiovascular franchise for Sanofi where he led U.S. business operations and product launches in more than 20 countries. Previously, he served as vice president and global brand leader for the cardiovascular division of Merck & Co, Inc. where, for more than 25 years, he took on roles of increasing responsibility within the Company’s cardiovascular and thrombosis franchises and led marketing for the launch of ezetimibe.

Sheldon will assume responsibility for the commercial team at Esperion.

Sheldon holds a Master of Business Administration from Monmouth University, and a Bachelor of Applied Science from Drexel University. He also completed the leadership program at The Wharton School.

Ashley Hall is Chief Development Officer.

Prior to joining ESPERION, Ashley was Global Regulatory Lead for Cardiovascular at Amgen and oversaw the regulatory strategy and global filings for the evolocumab program, leading to the world’s first approval of a PCSK9 inhibitor for cholesterol lowering.

Previously, Ashley was Vice President of Regulatory Affairs at Micromet, which was acquired by Amgen in March of 2012.

Prior to joining Micromet, Ashley was Vice President of Regulatory and Clinical Affairs at RevoGenex, and before that, Director of World Wide Regulatory Affairs with the oncology team at MedImmune.

Ashley held various roles of increasing responsibility in global regulatory affairs at Abraxis BioScience and at La Jolla Pharmaceutical Company.

Ashley has also worked in Global Regulatory Policy at Amgen and as a policy intern for Francis Collins at the National Human Genome Institute.

Ashley earned a Juris Doctorate at the University of San Diego School of Law and a Bachelor of Science in Biochemistry and Cell Biology at the University of California San Diego.

Ken is Chief Technical Operations

Prior to joining ESPERION, Ken was a consultant to start-ups and mid-size companies focused on CMC strategies, NDA preparation and launch readiness.

Previously, he served as VP Manufacturing at NPS Pharmaceuticals. Prior to NPS, Ken served as VP Technical Operations at Otsuka America Pharmaceuticals for five years and was responsible for US supply chain, clinical supplies, US-CMC Development, QC and Packaging Technologies.

Before Otuska, Ken served as VP Manufacturing and Supply Chain at Cephalon. Previously, he was at BMS for seventeen years in development and manufacturing roles and at JNJ for five years.

Ken is a Pharmacist and holds a BS, MS and PhD in Pharmaceutical Sciences from Rutgers University.

All trademarks are the property of their respective owners.